News

Denteric’s CEO Sean McLoughlin looks forward to connecting at J.P.M. 2026

Denteric awarded $2.5M CUREator+ Dementia and Cognitive Decline funding to support a phase I safety study in early-stage Alzheimer’s disease (AD) patients using Denteric’s GPV381 therapy.

Denteric is pleased to advise that it has completed recruitment and dosing of 3 cohorts in its Phase I GPV381 clinical trial.

Denteric is pleased to announce that its first subjects have been dosed today in its first in human safety study of GPV381, a therapy designed to treat severe periodontal disease.  The phase 1 study will assess safety and tolerability of the therapy in healthy subjects and is being conducted at Nucleus Networks Phase I Unit in Melbourne.

Round one provided support to Denteric, an early-stage biotech developing therapies targeting  Porphyromonas gingivalis (Pg) related diseases – initially focused on severe periodontal disease.

Recent success with Pfizer and Moderna vaccines to Covid-19 has proven efficacy of mRNA vaccines for viruses, but little is known about using mRNA against bacterial pathogens, which are equally abundant.

Denteric co-founder Professor Reynolds has been recognised for his outstanding achievement in translating scientific discoveries into globally successful products that prevent and treat oral disease.

CSL-backed biotech company Denteric has closed a $14 million funding round, enabling it to develop a vaccine for a gum disease that affects one in three adults globally, with a human clinical trial expected within three years.

A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd.